A Trial of Carboplatin-Paclitaxel with or Without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

About this Study

The purpose this study is to compare any good and bad effects of using Ramucirumab along with the usual chemotherapy combination (Carboplatin and Paclitaxel) to the usual chemotherapy combination alone.

Sponsor Protocol ID:S1701
IRB Number:2018-0173
Actively Enrolling
Interventional
Phase 2
May 28, 2019
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No

Inclusion CriteriaThis study was designed to include women and minorities, but was not designed to measure differences of intervention effects.

Exclusion CriteriaNone

Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:John Ruckdeschel
How to participate in our Clinical Trials